e-learning
resources
Berlin 2001
Sunday 23.09.2001
New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab, a novel therapy for severe allergic asthma
Source:
Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Session:
New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Session type:
Poster Discussion
Number:
346
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Omalizumab, a novel therapy for severe allergic asthma. Eur Respir J 2001; 16: Suppl. 31, 346
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Anti-IgE treatment: An alternative for severe allergic occupational asthma
Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors?
Year: 2012
Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation.
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab
Source: Annual Congress 2012 - Asthma: assessment and treatment
Year: 2012
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Omalizumab decreases IgE production in patients with severe allergic asthma
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis
Source: Eur Respir J 2004; 24: 330
Year: 2004
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Source: Eur Respir J 2001; 18: 254-261
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept